Follow the CORVEL CORP stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, CORVEL CORP has recorded 333 public disclosures. Market capitalisation: €3.2bn. The latest transaction was disclosed on 15 June 2026 (Cession). Among the most active insiders: CLEMONS V GORDON. Every trade is accessible without an account.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 333 declarations
CorVel Corp. (ticker: CRVL) is a U.S.-based healthcare services and claims-management company listed on the NASDAQ in the United States. For French-speaking investors in France, Belgium, or Switzerland, CorVel is best understood as a specialized provider of medical cost containment and claims administration solutions, with a business model built around workflow automation, data-driven decision support, and integrated service delivery. The company was founded in 1987 under the name FORTIS by V. Gordon Clemons and went public in 1991. Its headquarters are in Irvine, California, and it serves more than 1,000 clients, including employers, insurance carriers, and government entities.([corvel.com](https://www.corvel.com/company/investors/?utm_source=openai)) CorVel’s core offering is an integrated platform covering claims management, case management, medical bill review, provider network management (PPO), pharmacy-related solutions, disability management, and liability/auto claims services. The company primarily addresses workers’ compensation, liability, disability, and alternative risk programs. A key differentiator is its proprietary technology stack, including CareMC®, which helps customers manage claims files, trigger alerts, track exceptions, and improve visibility across the claims lifecycle. CorVel also emphasizes its AI-based rules engine, used to support medical review, compliance, and anomaly detection across large volumes of claims and billing data.([sec.gov](https://www.sec.gov/Archives/edgar/data/874866/000095017025076999/crvl-20250331.htm)) From a competitive standpoint, CorVel occupies a niche position. The company describes itself as the only independent publicly traded claims management and cost containment provider, which gives it a distinct profile versus broader healthcare services or insurance technology peers. Its competitive edge comes from combining software-enabled automation with outsourced operational services, allowing customers to reduce administrative burden and medical spend while improving processing speed and compliance. That model tends to support recurring revenue relationships and embeds the company deeply into customer workflows.([corvel.com](https://www.corvel.com/company/investors/?utm_source=openai)) CorVel’s geographic footprint is primarily domestic, focused on the United States, where it serves customers across multiple regions through a national service and provider network. Because its solutions are tied to state-level workers’ compensation rules, billing practices, and claims processes, regulatory expertise is an important part of its market positioning.([sec.gov](https://www.sec.gov/Archives/edgar/data/874866/000095017025076999/crvl-20250331.htm)) Recent developments point to a constructive operating trajectory. For the fiscal year ended March 31, 2025, CorVel reported revenue of $896 million, up from $795 million in the prior year, and highlighted continued investment in AI to enhance communications, bill review, and fraud/waste/abuse detection. The company also ended the period with no borrowings, underscoring a conservative balance-sheet profile. For investors, CorVel remains a profitable, technology-enabled healthcare services company with defensive end markets and a clear specialization in claims cost containment in the United States.([corvel.com](https://www.corvel.com/insights/corvel-announces-fiscal-year-revenues-and-earnings-fy-2025/?utm_source=openai))